Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma

Yao Chen¹, Wei-Jun Fu², Lan-Ping Xu¹, Han-Yun Ren³, Yong-Rong Lai⁴, Dai-Hong Liu⁵, Lin Liu⁶, Zi-Min Sun⁷, Yuan-Bin Wu⁸, Xin Wang⁹, Ling-Hui Xia¹⁰, Ming Jiang¹¹, Tong-Lin Hu¹², Ding-Ming Wan¹³, Xiao-Jun Huang¹,¹⁴

¹Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; ²Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China; ³Department of Hematology, Peking University First Hospital, Beijing 100034, China; ⁴Department of Hematology, The First Affiliated Hospital of Guangdong Medical University, Nanning, Guangxi 530021, China; ⁵Department of Hematology, Chinese People’s Liberation Army General Hospital, Beijing 100853, China; ⁶Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China; ⁷Department of Hematology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, China; ⁸Department of Hematology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510530, China; ⁹Department of Hematology, Shandong Provincial Hospital, Jinan, Shandong 250021, China; ¹⁰Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University; Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, Xinjiang 830054, China; ¹¹Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Zhejiang International Exchange Center of Clinical Traditional Chinese Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China; ¹²Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China; ¹³Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China; ¹⁴Peking-Tsinghua Center for Life Sciences, Beijing 100871, China.

Abstract

Background: Allogeneic stem-cell transplantation (SCT) is a well-established immunotherapeutic strategy for multiple myeloma (MM) with a potent and often sustained graft-vs.-myeloma effect. This multicenter investigation aimed to analyze the complications and survival of haploidentical SCT in patients with MM, and compare the main outcomes with matched-related donors (MRDs).

Methods: Haploidentical and MRD SCT was identified from a cohort of 97 patients with MM who received a myeloablative transplantation in 13 hospitals from May 2001 to December 2017. A matched-pair analysis was designed. For each haplo recipient, the recipients were randomly selected from the MRD group and were matched according to the following criteria: year of the hematopoietic SCT (±2 years), disease status at transplantation, and the length of follow-up.

Results: Seventy cases received MRD and 27 received haploidential transplantation. The two groups showed no significant differences regarding age, gender, cytogenetic risk, and diagnostic stage. The cumulative incidences of non-relapse mortality (NRM) at 1 and 3 years based on donor type were 20.5% (95% CI, 9.58–31.45%) and 24.2% (95% CI, 13.81–34.59%) for the MRD group and 16.80% (95% CI, 1.71–31.89%) and 28.70% (95% CI, 8.71–48.69%) for the haplo group, respectively. Cumulative incidence of NRM did not differ significantly between the two groups (χ² = 0.031, P = 0.861). The cumulative incidences of progression-free survival (PFS) and 1 year and 3 years by type of donors were 59.8% (95% CI, 48.24–71.36%) and 45.4% (95% CI, 33.44–57.36%), and 65.6% (95% CI, 47.18–84.02%) and 26.8% (95% CI, 7.59–46.01%) for MRD and haploidential donor, respectively. Cumulative incidence of PFS did not differ significantly between the two groups (χ² = 1.82, P = 0.670). In multivariate analyses, no statistically significant differences were observed between haploidential and MRD for relapse, NRM, PFS, and overall survival. There were no statistically significant differences on main outcomes after haploidential and MRD.

Conclusion: Haploidential SCT could be performed safely and feasibly for patients with MM in need.

Keywords: Allogeneic stem-cell transplantation; Multiple myeloma

Yao Chen and Wei-Jun Fu contributed equally to this study.

Correspondence to: Prof. Xiao-Jun Huang, Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Peking-Tsinghua Center for Life Sciences, 11 Xizhimen South Street, Beijing 100044, China E-Mail: huangxiaojun@bjmu.edu.cn

Copyright © 2019 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2019;132(15) Received: 25-03-2019 Edited by: Yuan-Yuan Ji
Introduction

Allogeneic stem-cell transplantation (allo-SCT) is a well-established immunotherapeutic strategy for multiple myeloma (MM) with a potent and often sustained graft-vs.-host disease (GVHD) effect. Therefore, allo-SCT continues to be offered to a significant portion of patients with relapsed/refractory or ultra-high-risk MM. During early stage of this treatment, treatment-related mortality (TRM) following allo-SCT for MM has reportedly ranged from 40% to 60%. Since then, the TRM after myeloablative and reduced intensity conditioned allo-SCT has decreased with time (48% TRM between 1995 and 2000 vs. 29% TRM between 2001 and 2005) and further improvements are expected owing to improvements in supportive care and new preparative regimens.

Transplantation from a haploidentical family donor has become an established procedure to treat patients with malignant hematologic diseases including relapsed or refractory acute leukemia and lymphoma and serves as a treatment alternative for high-risk hematologic malignant disorders. Modified or intensified conditioning regimens and improved supportive care has yielded improved outcomes after haploidentical SCT (haplo-SCT) with decreased treatment-related toxicity and infections, compared to conventional SCT. Haplo-SCT has received increasing attention as an alternative to human leukocyte antigen (HLA)-matched SCT in emergent cases. However, limited information is available regarding the use of other alternative donors, such as haploidentical grafts in patients with MM. Previously, we reported the safety and efficacy of using grafts from matched sibling donors to treat MM. Accordingly, we performed a registry-based study to evaluate the outcomes of transplantation among patients receiving grafts from various donor types including matched siblings and haploidentical-related donors to analyze the role of donor type in MM.

Methods

Ethical approval

The study was conducted in accordance with the tenets of the Declaration of Helsinki. All patients provided informed consent for research. As a retrospective study and data analysis was performed anonymously, this study was exempt from the ethical approval.

Study design, inclusion criteria, and data collection

This retrospective registry-based study involved consecutively data on Chinese patients aged over 18 years and diagnosed with MM or plasma cell leukemia (PCL), receiving allogeneic SCT from May 2001 to December 2017. Exclusion criteria were as follows: history of allo-SCT, unrelated donors, non-myeloablative conditioning regimens, received cord blood as a source of stem cells, and unknown donor type. Patients with matched-related donors (MRDs) were assigned to the MRD group; patients with haploidentical-related donors, haplo group. A matched-pair analysis was designed. For each haplo recipient, the recipients were randomly selected from the MRD group and were matched according to the following criteria: year of the hematopoietic SCT (±2 years), disease status at transplantation and the length of follow-up.

Endpoints and definitions

The primary endpoint was progression-free survival (PFS) defined as time from allogeneic SCT to progression, relapse, or death from any cause, whichever occurred first. Secondary endpoints were neutrophil and platelet recovery, acute, and chronic graft-vs.-host disease (GVHD), non-relapse mortality (NRM), relapse incidence, and overall survival (OS). OS was defined as time from transplant to death from any cause.

Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count ≥0.5 × 10^9/L, without evidence of autologous reconstitution. Platelet engraftment was defined as the first date at which an unsupported platelet count of ≥20 × 10^9/L for 7 consecutive days was achieved. GVHD was evaluated on the basis of standard criteria.

Response to treatment was defined in accordance with standard criteria defined previously. Complete response (CR) was defined by negative serum and urine immunofixation and 5% or less plasma cells with normal morphologic features in a bone marrow aspirate. A very good partial response (VGPR) was defined as a 90% reduction in serum paraprotein levels; partial response (PR), a 50% reduction in serum paraprotein levels or a 90% reduction in Bence-Jones protein levels (including patients with Bence-Jones protein alone) or both; stable disease (SD), no change in serum paraprotein levels; progressive disease (PD), a 25% increase in serum paraprotein levels; relapse, resurgence of serum paraprotein, recurrence of bone marrow infiltration, or both in patients displaying a CR and a 50% increase beyond the plateau levels of serum paraprotein in two samples obtained 4 weeks apart from a responder. High-risk cytogenetic abnormalities included del17p, t(4;14), or t(14;16), analyzed via fluorescence in situ hybridization, or conventional metaphase cytogenetics.

Statistical analysis

Categorical variables and quantitative data from the haploidentical and MRD groups were compared using the Chi-squared test and the non-parametric test, respectively. PFS and OS were measured in days and calculated from the date of allo-SCT until the respective events. NRM was defined as death from any cause, which occurred without previous progression or relapse after transplantation. The univariate probabilities of acute GVHD (aGVHD), chronic GVHD (cGVHD), NRM, relapse, OS, and PFS
were calculated using cumulative incidence curves to account for competing risks. The effect of donor type on NRM, relapse, OS, and PFS was assessed using the Cox regression analysis. Any covariates with a $P$-value of <0.1 on univariate analysis were included in the multivariate analysis. All $P$-values were based on two-sided hypothesis tests, and the $a$-value was set at 0.05. The endpoint of the last follow-up for all surviving patients was October 14, 2018. SPSS 19.0 (IBM, Chicago, IL, USA) was used for statistical analysis.

### Results

Patient and transplant characteristics are summarized in Table 1. From 2001 to 2017, 97 patients from 13 centers, who fulfilled the eligibility criteria, were included. The median age at transplantation was 45 (range, 25–63) years. The median time from diagnosis to transplantation was 265 (range, 78–2619) days. Diagnosis was MM for 93 (95.9%) patients and PCL for four (4.1%) patients. Only 12 (12.4%) patients

| Characteristics | Total $(n = 97)$ | Haploidentical $(n = 27)$ | Identical sibling $(n = 70)$ | Statistics | $P$ |
|-----------------|-----------------|---------------------------|----------------------------|------------|----|
| Age (years), median (range) | 45 (25–63) | 46 (30–60) | 45 (25–63) | 0.519‡ | 0.604 |
| Gender, n (%) | | | | 4.006† | 0.045 |
| Female | 33 (34.0) | 5 (18.5) | 28 (40.0) | | |
| Male | 64 (66.0) | 22 (81.5) | 42 (60.0) | | |
| Diagnosis, n (%) | | | | 1.020† | 0.312 |
| MM | 93 (95.9) | 25 (92.6) | 68 (97.1) | | |
| PCL | 4 (4.1) | 2 (7.4) | 2 (2.9) | | |
| Myeloma type, n (%) | | | | 5.954† | 0.311 |
| IgG | 62 (63.9) | 19 (70.4) | 43 (61.4) | | |
| IgA | 9 (9.3) | 3 (11.1) | 6 (8.6) | | |
| IgD | 4 (4.1) | 0 | 4 (5.7) | | |
| Lambda or kappa light chain | 18 (18.6) | 4 (14.8) | 14 (20.0) | | |
| Non-secretory | 3 (3.1) | 0 | 3 (4.3) | | |
| Missing | 1 (1.0) | 1 (3.7) | 0 | | |
| Durie-Salmon stage, n (%) | | | | 1.600† | 0.449 |
| I | 1 (1.0) | 0 | 1 (1.5) | | |
| II | 8 (8.2) | 3 (11.1) | 5 (7.1) | | |
| III | 56 (57.7) | 11 (40.7) | 45 (64.3) | | |
| Missing | 32 (33.1) | 13 (48.2) | 19 (27.1) | | |
| Cytogenetic abnormalities, n (%) | | | | 5.348† | 0.061 |
| High risk | 20 (20.6) | 7 (25.9) | 13 (18.6) | | |
| Other alterations | 13 (13.4) | 1 (3.7) | 12 (17.1) | | |
| Normal | 42 (43.3) | 10 (37.1) | 32 (45.7) | | |
| Not performed/missing | 22 (22.7) | 9 (33.3) | 13 (18.6) | | |
| Status at transplantation, n (%) | | | | 17.067† | 0.009 |
| CR | 27 (27.8) | 10 (37.0) | 17 (24.3) | | |
| VGPR | 25 (25.8) | 1 (3.7) | 24 (34.3) | | |
| PR | 24 (24.7) | 6 (22.2) | 18 (25.7) | | |
| SD | 6 (6.2) | 3 (11.1) | 3 (4.3) | | |
| PD | 8 (8.2) | 2 (7.4) | 6 (8.6) | | |
| Relapse | 5 (5.2) | 4 (14.8) | 1 (1.4) | | |
| NR | 2 (2.1) | 1 (3.7) | 1 (1.4) | | |
| Previous ASCT, n (%) | | | | 6.341† | 0.012 |
| CR | 12 (12.4) | 7 (25.9) | 5 (7.1) | | |
| Median time from the diagnosis to the transplantation (days), mean (range) | 265 (78–2619) | 407 (113–1373) | 252 (78–2619) | | 0.100 |
| MNC infused per kg (×10⁸), median (range) | 8.10 (1.20–18.45) | 8.49 (3.93–18.45) | 7.44 (1.20–16.90) | 2.504† | 0.012 |
| CD34+ infused per kg (×10⁶), median (range) | 2.83 (0.53–21.64) | 2.83 (1.80–21.64) | 2.83 (0.53–13.70) | 1.089‡ | 0.276 |
| GVHD prophylaxis, n (%) | | | | 3.226‡ | 0.012 |
| Cyclosporin A containing | 90 (92.8) | 23 (85.2) | 67 (95.7) | | |
| Others | 7 (7.2) | 4 (14.8) | 3 (4.3) | | |
| TBI use, n (%) | 12 (12.4) | 7 (25.9) | 5 (7.1) | | |
| Year of transplantation, n (%) | | | | 6.341† | 0.006 |
| 2001–2009 | 24 (24.7) | 5 (18.5) | 19 (27.1) | | |
| 2010–2017 | 73 (75.3) | 22 (81.5) | 51 (72.9) | | |

‡ $Z$ values by non-parametric test. † $x^2$ values by Chi-squared test. MM: Multiple myeloma; PCL: Plasma cell leukemia; CR: Complete response; VGPR: Very good partial response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NR: No response; ASCT: Autologous stem-cell transplantation; MNC: Mononuclear cell; GVHD: Graft-vs.-host disease; TBI: Total-body irradiation.
received a previous autologous stem cell graft. Data from cytogenetic analysis were available for 75 patients, revealing cytogenetic abnormalities in 33 of 75 (44.0%) patients. High-risk abnormalities (del17p or t[4;14] or t[14;16]) were observed in 20 patients. Thirty-three patients (34.0%) received allo-SCT as first-line therapy, 64 (66.0%) received allo-SCT beyond first-line treatment. Eleven (15.7%) and ten (37.0%) patients in the MRD and haplo groups had a PR status less than that of SD, PD, and NR, respectively (P = 0.009). The most common conditioning regimen was BU and cyclophosphamide (CTX) administered to 62 (63.9%) patients. The combination of cyclosporine A (CsA), mycophenolate mofetil, and a short course of MTX was the most frequent (n = 90, 92.8%) GVHD prophylaxis. Peripheral blood stem cells were the most frequently used as stem cell sources for 56 of 97 (57.7%) transplants, whereas combined bone marrow and peripheral blood stem cells were used in 37 transplants (38.1%).

**Hematologic engraftment**

The 21-day cumulative incidences of neutrophil recovery for the MRD and haplo groups were 94.3% (95% confidence interval [CI], 88.8–99.8%) and 92.3% (95% CI, 82.1–100%), respectively (χ² = 3.791, P = 0.052). The 60-day cumulative incidences of platelet recovery for the MRD and haplo groups were 97.0% (95% CI, 92.9–100%) and 92.3% (95% CI, 82.1–100%), respectively. Platelet engraftment was significantly lower in the haplo group than in the MRD group (χ² = 3.729, P = 0.030).

**Acute and chronic GVHD**

Cumulative incidences of grades 2 to 4 acute GVHD at day 100 were 29.2% (95% CI, 18.0–40.4%), and 23.0% (95% CI, 6.9–39.1%) for MRD and haplo groups, while the corresponding probabilities of grade 3 or 4 acute GVHD on day 100 were 7.1% (95% CI, 1.0–13.2%) and 3.7% (95% CI, 0–10.8%), respectively; the risk of acute GVHD being similar between the two groups (χ² = 0.142, P = 0.05).

For the entire patient cohort, the 3-year cumulative incidence of chronic GVHD was 28.4% (95% CI, 14.7–42.1%) and 77.9% (95% CI, 52.4–100%) for MRD and haplo groups, respectively. The risk of chronic GVHD was significantly higher in the haplo group than in the MRD group (χ² = 3.897, P = 0.045).

**Other major outcomes**

Table 2 summarizes the causes of death in each group. The leading cause of death in the two groups was the recurrence of the primary disease. For the entire patient cohort, the 1- and 3-year cumulative incidences of NRM were 19.5% (95% CI, 11.46–27.54%) and 25.1% (95% CI, 15.89–34.31%), respectively. The cumulative incidences of NRM at 1 and 3 years based on donor type were 20.30% (95% CI, 10.90–30.10%) and 24.20% (95% CI, 13.81–34.59%) for the MRD group and 16.80% (95% CI, 1.71–31.89%) and 28.70% (95% CI, 8.71–48.69%) for the haplo group, respectively [Figure 1A]. Cumulative incidence of NRM did not differ significantly between the two groups (χ² = 0.031, P = 0.861). A transplantation later than 2010 was an independent significant factor that decreased NRM incidence upon multivariate analysis (hazard ratio [HR], 0.296; 95% CI, 0.132–0.663; P = 0.003).

Overall, at a median follow-up of 1390 days after transplantation, 35.1% patients had CR status. The cumulative incidences of relapse at years 1 and 3 based on donor type were 23.2% (95% CI, 14.03–36.37%) and 44.4% (95% CI, 30.68–58.12%) for the MRD group and 25.5% (95% CI, 7.66–43.34%) and 37.6% (95% CI, 33.69–81.51%) for the haplo group, respectively [Figure 1B]. Cumulative incidence of relapse did not differ significantly between the two groups (χ² = 0.865, 0.584, P = 0.900).

| Causes         | Haploidentical (n = 16) | Identical sibling (n = 31) |
|----------------|-------------------------|---------------------------|
| Relapse        | 9 (56.3)                | 14 (45.2)                 |
| Infection      | 2 (12.5)                | 5 (16.1)                  |
| GVHD           | 2 (12.5)                | 4 (12.9)                  |
| Unknown        | 3 (18.7)                | 8 (25.8)                  |

Haploidentical group vs. Identical sibling group, χ² = 0.584, P = 0.900.

MM: Multiple myeloma; PCL: Plasma cell leukemia; GVHD: Graft-vs-host disease.

**Figure 1:** The cumulative incidences of NRM, relapse, PFS, and OS in the MRD group and haplo group. (A) NRM in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). (B) Relapse in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). (C) PFS in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). (D) OS in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). MM: Multiple myeloma; MRD: Matched-related donor; NRM: Non-relapse mortality; PCL: Plasma cell leukemia; PFS: Progression-free survival; OS: Overall survival; SCT: Stem-cell transplantation.
A status lower than PR at transplantation was an independent risk factor for relapse upon multivariate analysis (HR, 2.483; 95% CI, 1.251–4.925; \( P = 0.009 \)).

The cumulative incidences of PFS at years 1 and 3 based on donor type were 59.8% (95% CI, 48.24–71.36%) and 45.4% (95% CI, 33.44–57.36%) for the MRD group and 65.6% (95% CI, 47.18–84.02%) and 26.8% (95% CI, 7.59–46.01%) for the haplo group, respectively [Figure 1C]. Cumulative incidence of PFS did not differ significantly between the two groups (\( \chi^2 = 0.182, \ P = 0.670 \)). Furthermore, a status lower than PR was an independent risk factor for relapse upon multivariate analysis (HR, 1.939; 95% CI, 1.108–3.393; \( P = 0.02 \)).

The cumulative incidences of OS at years 1 and 3 were 72.8% (95% CI, 62.41–83.19%) and 60.1% (95% CI, 48.34–71.86%) for the MRD group and 68.8% (95% CI, 50.77–86.83%) and 37.5% (95% CI, 15.94–59.06%) for the haplo group, respectively [Figure 1D]. The probabilities of OS did not differ significantly between the two groups (\( \chi^2 = 1.484, \ P = 0.223 \)).

### Table 3: Univariate and multivariate analyses of factors influencing NRM and relapse for transplantation with donor type.

| Items               | NRM univariate | NRM multivariate | Relapse univariate | Relapse multivariate |
|---------------------|----------------|------------------|-------------------|---------------------|
|                     | HR  | 95%CI | \( P \) | HR  | 95%CI | \( P \) | HR  | 95%CI | \( P \) | HR  | 95%CI | \( P \) |
| Gender              |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| Male                |     |       |       | 0.943| 0.402–2.212| 0.892| 0.892| 0.455–1.749| 0.74 |
| Female              |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| Age                 |     |       |       | 0.782| 0.332–1.844| 0.575| 0.719| 0.383–1.352| 0.306|
| Type                |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| MRD                 |     |       |       | 1.281| 0.529–3.104| 0.584| 1.359| 0.671–2.753| 0.395|
| Haplo               |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| Status              |     |       |       | 1.206| 0.450–3.236| 0.71 | 2.483| 1.251–4.925| 0.009|
| CR-PR               |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| Relapse-NR-SD-PD    |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| Cytogenetics        |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| Standard            |     |       |       | 1.197| 0.394–3.637| 0.752| 1.498| 0.685–3.275| 0.311|
| High risk           |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| Diagnosis time      |     |       |       | 1.54 | 0.683–3.471| 0.298| 1.354| 0.720–2.546| 0.348|
| Conditioning        |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| TBI                 |     |       |       | 1.086| 0.323–3.647| 0.894| 2.140| 0.855–5.354| 0.104|
| MNC                 |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| <Median             |     |       |       | 0.769| 0.325–1.819| 0.55 | 0.985| 0.585–1.659| 0.955|
| ≥Median             |     |       |       | 1.109| 0.411–2.991| 0.837| 0.822| 0.482–1.613| 0.683|
| CD34+ dose          |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |
| <Median             |     |       |       | 0.326| 0.132–0.663| 0.003| 0.296| 0.132–0.663| 0.003|
| ≥Median             |     |       |       | 1    |       |       | 1    |       |       | 1    |       |       |

NRM: Non-relapse mortality; MRD: Matched-related donor; HR: Hazard ratio; CI: Confidence interval; CR: Complete response; VGPR: Very good partial response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NR: No response; TBI: Total-body irradiation; MNC: Mononuclear cell.
25.1%, respectively, in MRD and haplo recipients. Notably, the cumulative incidence of NRM at 1 and 3 years were comparable between the MRD and haplo groups. Twenty-eight-day neutrophil recovery was not significantly different between the haplo and MRD groups. Furthermore, the cumulative incidence of either grade acute GVHD was comparable between the two groups; however, the haplo group displayed a greater frequency of chronic GVHD than the MRD group. Compared with the MRD population, the possibility of those with an increased incidence of chronic GVHD having a relatively beneficial graft-vs.-myeloma effect warrants verification via further case studies.

Better clinical outcomes are probably associated myeloma chemosensitivity during transplantation. Patients with a status lower than PR did not benefit from allo-SCT and had a higher risk of relapse. Considering high-risk features, cytogenetic aberrations are notably associated with an unfavorable prognosis in patients with MM receiving standard therapies. In the current study, high-risk cytogenetic aberrations were not a poor prognostic factor for major outcomes. Concurrent with the observation by Schilling et al and Roos-Weil et al, allo-SCT might overcome the adverse prognosis of high-risk cytogenetic aberrations.[23,24] Overall, the risk of relapse was still high even after allo-SCT. In our series, the cumulative incidence of relapse at 3 years was as high as 44.4% and 57.6% the for MRD and haplo groups, respectively; however, these rates are comparable to previous reports regarding allo-SCT for MM. Notably, approximately 85% were of a CR/VGPR/PR status before transplantation in the MRD group; however, those in the haplo group were less chemosensitive (63%). Although pre-transplantation remission rates are important, molecular evaluation of minimal-residual disease significantly influences the detection of disease recurrence,[23,26] where immediate therapeutic intervention could extend the duration of remission and survival in a low-risk situation. Therefore, strategies to prevent relapse after allo-SCT may include a series of minimal

| Table 4: Univariate and multivariate analyses of factors influencing PFS and OS for transplantation with donor type. |
|---------------------------------------------------------------|
| **Items**                               | **PFS univariate** | **PFS multivariate** | **OS univariate** | **OS multivariate** |
|-----------------------------------------|--------------------|----------------------|------------------|---------------------|
| Gender                                  |                    |                      |                  |                     |
| Male                                    | 1                  |                      | 1                |                     |
| Female                                  | 0.929 (0.548–1.576) | 0.785                | 0.799 (0.425–1.501) | 0.485              |
| Age                                     |                    |                      |                  |                     |
| < Median age                             | 1                  |                      | 1                |                     |
| ≥ Median age                             | 0.84 (0.505–1.396)  | 0.501                | 0.762 (0.419–1.386) | 0.373              |
| Type                                     |                    |                      |                  |                     |
| MRD                                     | 1                  |                      | 1                |                     |
| Haplo                                    | 1.301 (0.747–2.264) | 0.353                | 1.632 (0.877–3.037) | 0.122              |
| Status                                  |                    |                      |                  |                     |
| CR-PR                                    | 1                  |                      | 1                |                     |
| Relapse-NR-SD-PD                        | 1.939 (1.108–3.393) | 0.02                 | 1.939 (1.108–3.393) | 0.02               |
| High risk                                | 1.341 (0.721–2.492) | 0.354                | 1.097 (0.532–2.262) | 0.802              |
| Diagnosis time                          |                    |                      |                  |                     |
| < Median                                | 1                  |                      | 1                |                     |
| ≥ Median                                | 1.537 (0.932–2.534) | 0.092                | 1.213 (0.680–2.165) | 0.513              |
| Conditioning                            |                    |                      |                  |                     |
| TBI                                     | 1                  |                      | 1                |                     |
| None-TBI                                | 2.109 (0.842–5.284) | 0.111                | 1.74 (0.623–4.862) | 0.291              |
| MNC                                     |                    |                      |                  |                     |
| < Median                                | 1                  |                      | 1                |                     |
| ≥ Median                                | 1.007 (0.587–1.729) | 0.98                 | 0.716 (0.385–1.333) | 0.292              |
| CD34+ dose                              |                    |                      |                  |                     |
| < Median                                | 1                  |                      | 1                |                     |
| ≥ Median                                | 0.836 (0.455–1.536) | 0.563                | 0.77 (0.379–1.562) | 0.469              |
| Transplant year                         |                    |                      |                  |                     |
| 2001–2009                               | 1                  |                      | 1                |                     |
| 2010–2017                               | 0.793 (0.461–1.363) | 0.401                | 0.568 (0.308–1.048) | 0.07               |
| **PFS:** Progression-free survival; **OS:** Overall survival; **HR:** Hazard ratio; **CI:** Confidence interval; **MRD:** Matched-related donor; **CR:** Complete response; **VGPR:** Very good partial response; **PR:** Partial response; **SD:** Stable disease; **PD:** Progressive disease; **NR:** No response; **TBI:** Total-body irradiation; **MNC:** Mononuclear cell. |
residual disease monitoring and maintenance with immunomodulatory drugs, proteasome inhibitors, or targeted cell immunotherapy.16–29

Naturally, the present study has some limitations inherent to a retrospective analysis. First, conditioning regimens differed and were not standardized. A few regimens included TBI, no significant effect was observed in the outcomes between the TBI and non-TBI groups. Second, maintenance therapy differed and were not standardized. A few regimens included TBI, no significant effect was observed in the outcomes between the TBI and non-TBI groups. Third, maintenance therapy remains a key issue, even in chemosensitive patients treated first via allo-SCT. In addition, strategies to enhance a graft-vs.-myeloma effect after transplantation should be investigated to decrease disease progression.

Funding
This work was supported by grants from Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 81621001), and National Natural Science Foundation of China (Nos. 81670167 and 81670166).

Conflicts of interest
None.

References
1. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196–1198. doi: 10.1088/1439-0333.2002.011-02619.x.
2. Mohry M, Borer JM, Damaj G, Michallet AS, Bay JO, Faucher G, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation 2004;34:77–84. doi: 10.1038/sj.bmt.1704531.
3. Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR, et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol 1989;43:186–190. doi: 10.1111/j.1600-0609.1989.tb01515.x.
4. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787–2793. doi: 10.1088/1439-0333.2002.011-02619.x.
5. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:471–478. doi: 10.1088/1439-0333.2002.011-02619.x.
6. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial III 9201. J Clin Oncol 2006;24:929–936. doi: 10.1200/JCO.2005.04.5807.
7. Kumar S, Zhang MJ, Peigang L, Dispensieri A, Milone GA, Lonal S, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011;118:1979–1988. doi: 10.1182/blood-2011-02-337294.
8. Solomon SR, Szemere CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack donor stem cells. Biol Blood Marrow Transplant 2016;22:1861–1866. doi: 10.1016/j.bbmt.2016.06.026.
9. Giralt S, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, et al. T-cell-replete HLA haploidentical donor transplantation with post-transplant cyclophosphamide is an effective salvage for patients relapsing after an HLA-matched related or matched unrelated donor transplantation. Biol Blood Marrow Transplant 2016;22:1861–1866. doi: 10.1016/j.bbmt.2016.06.026.
10. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical versus matched-sibling transplantation in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res 2016;22:3467–3476. doi: 10.1158/1078-0432.CCR-15-2335.
11. How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, et al. T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia. Biol Blood Marrow Transplant 2017;23:648–653. doi: 10.1016/j.bbmt.2017.01.063.
12. Rusby A, Zhang X, Szemere CA, Marion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013;31:1310–1316. doi: 10.1200/JCO.2012.44.3523.
13. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplants for AML in remission: a multicenter, prospective study. Blood 2015;125:3595–3562. doi: 10.1182/blood-2015-02-627786.
14. McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HH, Shawel MM, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplant cyclophosphamide. Haematologica 2017;102:391–400. doi: 10.3324/haematol.2016.144139.
15. Castagna L, Mussetti A, Devillier R, Dominiello A, Marcatti M, Milone G, et al. Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post transplant cyclophosphamide GVHD prophylaxis. Biol Blood Marrow Transplant 2017;23:1549–1554. doi: 10.1016/j.bbmt.2017.05.006.
16. Chen Y, Lu J, Xu LP, Chen H, Zhang XH, Wang FR, et al. Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2018;53:507–510. doi: 10.1038/s41409-017-0069-1.
17. Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, et al. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Chin Med J 2007;120:463–468. doi: 10.1016/j.jjca.2006.03.010.
18. Lan HF, Yuan ZG, Zhang CY, Chen YB, Fu WJ, Jiang H, et al. Allogeneic peripheral blood stem cell transplantation from sibling donors for 10 patients with multiple myeloma [in Chinese]. Chin J Hematol 2012;33:191–194. doi: 10.3760/cma.j.issn.0253-2727.2012.03.010.
19. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009;15:367–369. doi: 10.1016/j.bbmt.2008.12.497.
20. Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, et al. Hematopoietic stem cell transplantation in multiple myeloma: a retrospective study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant 2015;21:1452–1459. doi: 10.1016/j.bbmt.2015.04.020.

21. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473. doi: 10.1038/sj.leu.2404284.

22. Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia 2016;30:2047–2054. doi: 10.1038/leu.2016.101.

23. Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón JA, Gutierrez NC, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008;22:1250–1255. doi: 10.1038/leu.2008.88.

24. Roos-Weil D, Moreau P, Avet-Loiseau H, Golmard JL, Kuentz M, Vigouroux S, et al. Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 2011;96:1504–1511. doi: 10.3324/haematol.2011.042713.

25. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927–1929. doi: 10.1182/blood-2003-01-0189.

26. Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalhy H, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013;19:398–404. doi: 10.1016/j.bbmt.2012.10.008.

27. Ladetto M, Ferrero S, Drandi D, F胥cuccia M, Patriarca F, Mordìni N, et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia 2015;30:1211–1214. doi: 10.1038/leu.2015.269.

28. Michallet M, Sobh M, El-Cheikh J, Morisset S, Sirvent A, Reman O, et al. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Exp Hematol 2013;41:1008–1015. doi: 10.1016/j.exphem.2013.08.003.

29. Caballero-Velázquez T, López-Corral I, Encinas C, Castilla-Llorente C, Martino R, Rosati L, et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol 2013;162:474–482. doi: 10.1111/bjh.12410.